Image : https://19j7mk3co2lu2b2wgr27dgh5-wpengine.netdna-ssl.com/wp-content/uploads/sites/21/2019/01/bronchiasthmaattackmi01b0vgx_1422369-860x632.jpg

Latifa Chachi, Sarah Diver, Himanshu Kaul, Marlon C. Rebelatto, Anmarie Boutrin, Patricia Nisa, Paul Newbold, Christopher Brightling

European Respiratory Journal 2019 54: 1900930; DOI: 10.1183/13993003.00930-2019

Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma

Extract

Asthma is a heterogeneous condition characterised by chronic inflammation and airway remodelling. T2-mediated airway inflammation, characterised by interleukin (IL)-4, IL-5 and IL-13, has been the recent focus of pharmacotherapy, with a host of targeted biologic agents now available to clinicians [1]. The anti-IL-5 receptor agent, benralizumab, causes depletion of eosinophils and basophils via antibody-dependent cell-mediated cytotoxicity in blood; however, the mechanism of action in the tissue is uncertain. Benralizumab has reduced exacerbations and improved lung function in clinical trials.

Footnotes

• This study is a post-analysis from a previous clinical trial (NCT00659659).

• Conflict of interest: L. Chachi has nothing to disclose.

• Conflict of interest: S. Diver has nothing to disclose.

• Conflict of interest: H. Kaul reports grants from AirPROM, during the conduct of the study.

• Conflict of interest: M.C. Rebelatto is an employee of and owns shares in AstraZeneca.

• Conflict of interest: A. Boutrin is an employee of and holds stock options in AstraZeneca.

• Conflict of interest: P. Nisa has nothing to disclose.

• Conflict of interest: P. Newbold is an employee of and owns shares in AstraZeneca.

• Conflict of interest: C. Brightling reports grants and personal fees for consultancy from GlaxoSmithKline, AstraZeneca/Medimmune, Novartis, Chiesi, Roche/Genentech and Boehringer Inglheim, personal fees for consultancy from Vectura, Theravance, PreP, Gilead, Sanofi/Regeneron, Teva, Gossamer and 4DPharma, grants from Pfizer and Mologic, outside the submitted work.